Form 4: Revolution Medicines CEO Sells Shares Under 10b5-1 Plan

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Mark A. Goldsmith, President and Chief Executive Officer, and a Director of Revolution Medicines, Inc. (RVMD), reported transactions involving the company's common stock.
• The transactions, which occurred on October 16, 2025, and October 17, 2025, were executed pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.
• On both October 16, 2025, and October 17, 2025, Goldsmith exercised options to acquire 10,000 shares of common stock at an exercise price of $1.12 per share.
• Immediately following each option exercise, he sold 10,000 shares of common stock.
• The shares sold on October 16, 2025, had a weighted average price of $50.4701, while shares sold on October 17, 2025, were priced at $55.00.
• Following these reported transactions, Goldsmith directly beneficially owns 452,309 shares of common stock, which includes 193,475 restricted stock units.
• He also directly beneficially owns 26,479 stock options.
• Additionally, Goldsmith holds indirect beneficial ownership of 20,424 shares through the Jonathan Goldsmith Revocable Trust, 20,424 shares through the Rebecca Eve Goldsmith Trust, and 465,604 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Sentiment

Score: 5

Explanation: The transactions represent pre-planned insider selling under a 10b5-1 plan, which is a routine event for personal financial management and does not inherently signal a positive or negative outlook on the company's future performance.

Positives

• CEO Mark A. Goldsmith realized significant gains by exercising stock options at a low price of $1.12 per share and selling the acquired shares at market prices of $50.4701 and $55.00 per share.

Negatives

• CEO Mark A. Goldsmith sold a total of 20,000 shares of common stock, which could be perceived negatively by some investors, despite being part of a pre-arranged plan.

Future Outlook

NA

Management Comments

• Transactions were made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership is held through the Jonathan Goldsmith Revocable Trust, Rebecca Eve Goldsmith Trust, and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, which are related parties to Mark A. Goldsmith.

Stakeholder Impact

• Shareholders may interpret insider selling as a potential negative signal, although the execution under a pre-arranged 10b5-1 plan typically mitigates concerns about management's immediate view of the company's prospects.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes be viewed negatively, the pre-planned nature suggests it is for personal financial management rather than a reflection of a change in company outlook. Therefore, it does not provide a strong signal for a change in investment recommendation, warranting a 'hold' stance.

Keywords

Revolution Medicines, RVMD, Mark A. Goldsmith, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Share Sale